Medical device maker Truscreen is signalling it may need to raise more money from shareholders after posting an unaudited $3.5 million loss for the year to March.
The company produces an opto-electronic cervical cancer screening device that offers an alternative to conventional screening in
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
